Form 8-K - Current report:
SEC Accession No. 0001493152-25-002832
Filing Date
2025-01-17
Accepted
2025-01-17 17:20:13
Documents
18
Period of Report
2025-01-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 47184
2 ex4-2.htm EX-4.2 119408
3 ex4-3.htm EX-4.3 120947
4 ex10-1.htm EX-10.1 292702
5 ex10-3.htm EX-10.3 98776
  Complete submission text file 0001493152-25-002832.txt   990534

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE kapa-20250116.xsd EX-101.SCH 3027
7 XBRL LABEL FILE kapa-20250116_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE kapa-20250116_pre.xml EX-101.PRE 22367
21 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3801
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42275 | Film No.: 25539618
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)